Vicarious Surgical business combination clears NYSE listing
Vicarious Surgical shareholders approved its business combination with D8 Holdings, with RBOT shares set to trade on the NYSE.
Evidence notes
- The transaction was expected to provide approximately USD 220 million in gross proceeds.
- Proceeds supported development and planned commercialization of the Vicarious single-incision surgical robot.
Company context
Vicarious Surgical is developing a surgical robotics platform intended to provide minimally invasive access through a compact, patient-side robotic system.